Analyzing Analyst Recommendations: Alteryx, Inc. (AYX), Intellia Therapeutics, Inc. (NTLA)

Alteryx, Inc. (NYSE:AYX) tinted gains of +0.87% (+0.58 points) to US$67.6. The volume of 1.2 Million shares climbed up over an trading activity of 1.07 Million shares. EPS ratio determined by looking at last 12 month figures is -0.16. Over the same time span, the stock marked US$79.97 as its best level and the lowest price reached was US$30.45. The corporation has a market cap of US$4.32 Billion.

Alteryx, Inc. (NYSE:AYX)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -8.9 percent while most common profitability ratio return on investment (ROI) was -9.6 percent. The company’s institutional ownership is monitored at 99.13 percent. The company’s net profit margin has achieved the current level of -8.4 percent and possesses 87.8 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 4 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 4 think it is Hold. Recently, analysts have updated the overall rating to 2. 5 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is worth US$683.6 Million and has recently fallen -5.99% to US$15.54. The latest exchange of 0.63 Million shares is below its average trading activity of 642.27 Million shares. The day began at US$15.57 but the price moved to US$15.5 at one point during the trading and finally capitulating to a session high of US$15.59. The stock tapped a 52-week high of US$35.99 while the mean 12-month price target for the shares is US$37.31.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 2.47, and a price to sales ratio of 23.41. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 74.6%, it carries an earnings per share ratio of -2.16.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 3 brokerage firms polled by Factset Research. At present, 4 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.11.